Clinical trials: Atopic Eczema
Atopic Dermatitis
Dupilumab in Japanese Patients With Atopic Dermatitis
Primary Objective: To evaluate the efficacy of dupilumab administered concomitantly with topical corticosteroids (TCS) Secondary Objective: To evaluate the efficacy of dupilumab administered concomitantly with TCS.
- Trial name
- NCT04678882
- Testing
- Dupilumab SAR231893
- Where
- 19 sites in Japan
- Volunteers
- 62 people
- Sponsor
- Sanofi
Atopic Dermatitis
Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 330 subjects aged 12 to 75 years old with moderate to severe atopic dermatitis.
- Trial name
- NCT04875169
- Testing
- Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Extension Treatment Active Experimental: SHR0302 Dose#1
- Where
- 52 sites in Canada, China
- Volunteers
- 336 people
- Sponsor
- Reistone Biopharma Company Limited
Dermatitis, Atopic
An Observational Study to Gather Real-World User Feedback on DIPROBASE® Advanced Eczema Cream in Adults and Children With Eczema or Dry Skin
This is an observational study which means only data are collected from participants about their experience and symptoms, who received their usual treatment without any intervention from the study sponsor.
- Trial name
- NCT06747897
- Testing
- MINERAL OIL + PETROLATUM (DIPROBASE® Advanced Eczema Cream, BAY987534, UI 1613882)
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Bayer
Atopic Dermatitis
Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis
A Multicenter, Randomized, Single-Blind, Phase Ⅱ Clinical Trial and Open Label Long-term Observation Study of ADSTEM Inj. to Evaluate the Safety and Efficacy in Patients with Moderate to Severe Subacute and Chronic Atopic…
- Trial name
- NCT04137562
- Testing
- ADSTEM Inj.
- Where
- 6 sites in South Korea
- Volunteers
- 118 people
- Sponsor
- EHL Bio Co., Ltd.
Dermatitis, Atopic
A Phase 1 Study of KHK4083 in Subjects With Atopic Dermatitis
The objective of this study is to evaluate the safety and tolerability of multiple intravenous (IV) infusions of KHK4083 in subjects with moderate or severe atopic dermatitis.
- Trial name
- NCT03096223
- Testing
- KHK4083
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Dermatitis, Atopic
A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of MG-K10 monotherapy in adolescents with moderate-to-severe atopic dermatitis (AD)
- Trial name
- NCT07540442
- Testing
- MG-K10 Injection (Humanized Monoclonal Antibody)
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Atopic Dermatitis
Evaluation of the Efficacy of TOPIALYSE Baume Protect+ on Atopic Dermatis
The purpose of this study is to evaluate the efficacy and tolerability of a SVR care product. As we know, atopic dermatitis is a vicious circle that must be broken, but certain aggravating factors are added to this circle.
- Trial name
- TOPIAbis (NCT06108570)
- Testing
- Cosmetic Product TOPIALYSE Baume Protect+
- Where
- 3 sites in Belgium
- Volunteers
- 60 people
- Sponsor
- SVR Group
Atopic Dermatitis
Safety and Tolerability of BSI-045B in Healthy Adult Subjects and Patients With Atopic Dermatitis
This randomized, double-blind, single center, placebo-controlled, phase 1 single ascending dose (SAD)/multiple ascending dose (MAD) study is designed to assess the safety, tolerability, PK, activity, immunogenicity, and PD of…
- Trial name
- NCT05114889
- Testing
- BSI-045B
- Where
- Australia
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Biosion, Inc.
Atopic Dermatitis
A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis
This is a multicenter, double-blind, vehicle-control study of 0.05% and 0.2% E6005 ointment. Pediatric subjects with atopic dermatitis (AD) will be grouped into two; an elder group (childhood - adolescent: 7 to 15 years of age)…
- Trial name
- NCT02094235
- Testing
- E6005 0.05%, E6005 0.2%
- Where
- 3 sites in Japan
- Volunteers
- 62 people
- Sponsor
- Organon and Co
Adverse Pregnancy Outcomes, Atopic Dermatitis
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
The objective of this study is to describe and compare the incidence of adverse pregnancy outcomes (spontaneous abortion/miscarriage, stillbirth) and prevalence of adverse infant outcomes (major congenital malformations [MCMs]…
- Trial name
- NCT03936335
- Testing
- dupilumab
- Where
- United States
- Volunteers
- 12,343 people
- Sponsor
- Regeneron Pharmaceuticals
Dermatitis, Atopic
Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis
This study will evaluate efficacy and safety of GSK1070806 in moderate to severe atopic dermatitis (AtD) participants.
- Trial name
- NCT04975438
- Testing
- GSK1070806
- Where
- 11 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis, Atopic Dermatitis Eczema
Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the safety and efficacy of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis (AD)
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema
- Trial name
- NCT07734415
- Testing
- IMG-007
- Where
- 23 sites in United States, Canada
- Volunteers
- 400 people
- Sponsor
- Inmagene LLC
Atopic Dermatitis
A Phase Ⅲ Comparative Study of QL2108 to Dupixent®
It is a multicenter randomized, double-blinded, parallel, positive-controlled, Phase Ⅲ comparative study to evaluate the efficacy and safety of QL2108 to Dupixent® in adult subjects with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06884891
- Testing
- QL2108 injection, Dupixent®
- Volunteers
- 520 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Atopic Dermatitis Eczema
Pilot Study to Test the Effects of Arctiva on Mild to Moderate Eczema
Up to 30 participants with mild to moderate atopic dermatitis/eczema will be enrolled to apply study Investigational Product for 4 weeks.
- Trial name
- NCT05918237
- Testing
- Arctiva
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- ClinOhio Research Services, LLC
Allergy, Dermatitis
Randomized Study for Effectiveness and Safety Evaluation of Dexamethasone 0.5 mg + Fumarate Clemastine 1 mg Compared to Dexamethasone 0.5 mg in Patients With Allergic Dermatitis
The aim of this study is to prove the efficacy of the dexamethasone 0.5 mg + 1 mg clemastine fumarate tablet compared to 0.5 mg of dexamethasone in reducing the signs and symptoms of allergic dermatitis.
- Trial name
- NCT01239719
- Testing
- Dexamethasone + clemastine, Dexamethasone
- Volunteers
- 96 people
- Sponsor
- Azidus Brasil
Dermatitis, Atopic
Study to Evaluate the Efficacy and Safety of 0.1% and 0.03% Tacrolimus Ointment Administered in Adults With Moderate to Severe Atopic Dermatitis
The objective of this study is to assess the efficacy and safety of 0.1% and 0.03% Tacrolimus ointment for 12 months in adults with moderate to severe atopic dermatitis.
- Trial name
- NCT00691145
- Testing
- tacrolimus ointment
- Where
- 26 sites in Italy
- Volunteers
- 350 people
- Sponsor
- Astellas Pharma Inc
Dermatitis, Atopic
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
The purpose of this study is to investigate the safety and efficacy of AN2728 Topical Ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic dermatitis.
- Trial name
- NCT02118766
- Testing
- AN2728 Topical Ointment, 2%, Matching vehicle control
- Where
- United States
- Volunteers
- 763 people
- Sponsor
- Pfizer
Dermatitis, Atopic
A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis
The purpose of this non-interventional study is to learn about the safety and effectivness of Cibinqo Tablet for the possible treatment of atopic dermatitis (AD). AD is a long-lasting itchy red rash, caused by a skin reaction.
- Trial name
- NCT05391061
- Testing
- Abrocitinib
- Where
- South Korea
- Volunteers
- 1,100 people
- Sponsor
- Pfizer
Atopic Dermatitis
Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis
The purpose of this study is to identify how pimecrolimus cream 1% modifies the molecular and cellular changes associated with the post-lesional phase of atopic dermatitis (AD).
- Trial name
- NCT00117377
- Testing
- Pimecrolimus
- Where
- 3 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Novartis
Atopic Dermatitis (AD), Eczema
Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis
This is a Phase 2a efficacy and safety study of EVO301 for the treatment of adults with atopic dermatitis.
- Conditions
- Atopic Dermatitis (AD), Eczema, Eczema Atopic Dermatitis
- Trial name
- NCT06723405
- Testing
- EVO301
- Where
- 12 sites in Australia, New Zealand
- Volunteers
- 71 people
- Sponsor
- Evommune, Inc.